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Abstract 
We asked whether the antiangiogenic action of 16K human PRL (hPRL), in addition to blocking mitogen-
induced vascular endothelial cell proliferation, involved activation of programmed cell death. Treatment with 
recombinant 16K hPRL increased DNA fragmentation in cultured bovine brain capillary endothelial (BBE) and 
human umbilical vein endothelial (HUVE) cells in a time- and dose-dependent fashion, independent of the serum 
concentration. The activation of apoptosis by 16K hPRL was specific for endothelial cells, and the activity of the 
peptide could be inhibited by heat denaturation, trypsin digestion, and immunoneutralization, but not by 
treatment with the endotoxin blocker, polymyxin-B. 16K hPRL-in-duced apoptosis was correlated with the rapid 
activation of caspases 1 and 3 and was blocked by pharmacological inhibition of caspase activity. Caspase 
activation was followed by inactivation of two caspase substrates, poly (ADP-ribose) polymerase (PARP) and 
the inhibitor of caspase-activated de-oxyribonuclease (DNase) (ICAD). Furthermore, 16K hPRL increased the 
conversion of Bcl-X to its pro-apoptotic form, suggesting that the Bcl-2 protein family may also be involved in 
16K hPRL-induced apoptosis. These findings support the hypothesis that the antiangiogenic action of 16K hPRL 




Angiogenesis, the formation of new blood vessels, is a necessary component of physiological processes (1) as 
well as pathological conditions such as tumor growth and metastasis (2, 3). During angiogenesis, capillary 
endothelial cells proliferate, migrate into tissues, and organize into vessels. Migration and organization of 
endothelial cells into vessels requires concomitant activation of proteases necessary for tissue remodeling. This 
cascade of events is under the control of a balance of angiogenic and antiangiogenic factors. Factors known to 
stimulate the formation of new capillaries in vivo (1) include members of the fibroblast growth factors family 
(FGF) e.g. basic FGF (4) and vascular endothelial growth factor (VEGF) (5), angiogenin (6), and angiopoietin-1 
(7). Factors with antiangiogenic activity include platelet factor 4 (8), thrombospondin (9), the 16-kDa N-terminal 
fragment of PRL (16K PRL) (10, 11), angiostatin (12), and en-dostatin (13). More recently, Struman et al. (14) 
demonstrated that recombinant 16-kDa N-terminal fragments of related PRL family members including human 
GH, GH variant, and placental lactogen also have antiangiogenic activity (14). 
The antiangiogenic action of 16K PRL appears to affect the abilities of capillary endothelial cells to proliferate, 
migrate, and organize into vessels. A high-affinity, saturable, 16K PRL binding site that was independent from 
the PRL receptor was characterized on capillary endothelial cells (15). We showed that 16K PRL inhibited the 
proliferative effects of both basic FGF (bFGF) and VEGF on bovine brain capillary endothelial (BBE) cells 
(10,11). Considerable evidence supports the hypothesis that VEGF stimulates endothelial cell proliferation via 
activation of the mitogen-acti-vated protein kinase (MAPK) signaling cascade. Binding of VEGF to its receptor 
(Flk-1/KDR) results in au-tophosphorylation of the receptor, recruitment of the Shc/Grb2/Sos coupling proteins, 
and activation of Ras and downstream kinases leading to MAPK activation. We demonstrated that 16K human 
PRL (hPRL) inhibited VEGF-induced activation of MAPK (16). The blockade occurred distal to the activation 
of the Flk-1 and its association with coupling proteins (17). However, VEGF-induced Ras activation was 
inhibited by 16K hPRL, which is consistent with the inhibition of the downstream kinases, Raf-1 and MAPK. 
16K hPRL was shown to block the organization of BBE cells into polarized capillaries when cultured in type 1 
collagen gels (11). In vivo tissue remodeling, which accompanies the formation of new vessels, is dependent 
upon the activation of urokinase (uPA) (18). We showed that 16K hPRL inhibited uPA activity by activation of 
plasminogen activator inhibitor-type 1 (PAI-1) expression (19). 
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In addition to the inhibition of endothelial cell proliferation by antiangiogenic factors, there is recent evidence 
that angiostatin (20) and thrombospondin (21) also activate programmed cell death of endothelial cells. 
Extensive studies in past few years have led to the identification of many genes regulating programmed cell 
death during various physiological and pathological processes. Cells undergoing apoptosis are characterized by 
cytoplasmic shrinkage, membrane blebbing, chromatin condensation, DNA cleavage, and finally, cell 
fragmentation into membrane-bound apoptotic bodies. Caspase-mediated proteolysis of specific proteins results 
in this irreversible commitment to cell death (22). At least 13 caspases function as initiators or effectors of the 
apoptotic signaling pathway (23). Caspases exist as inactive proenzymes, which are activated by cleavage at 
specific aspartate residues, followed by assembly into heterotetramers. Activation of a caspase can result in 
stimulation of additional caspases, e.g. autocatalytic activation of caspase 1 by self-aggregation in turn activates 
caspase 3 (24). Another regulatory component of the apoptotic pathway is the Bcl-2 protein family. These 
proteins are believed to act at the level of, or upstream to, the caspases to inhibit or facilitate the apoptotic 
cascade. Antiapoptotic factors include Bcl-2 and Bcl-XL, while proapoptotic factors include Bax, Bak, Bad, and 
Bcl-Xs (25). 
In the current study, we asked whether 16K hPRL could activate programmed cell death as an additional 
mechanism for inhibiting angiogenesis. We show that 16K hPRL, but not native 23-kDa PRL, activates DNA 
fragmentation, and that apoptosis requires activation of the caspase cascade. We demonstrate that the apoptosis-
inducing action of the 16K hPRL preparations is dependent on the activity of the peptide and not on endotoxin 
contamination. Unlike the inhibition of mitogen-induced cell proliferation by 16K hPRL, treatment with 16K 
hPRL directly activates apoptosis. These findings provide the first detailed and specific analysis of the 
mechanisms regulating the activation of apoptosis by an antiangiogenic factor. 
 
RESULTS 
Stimulation of DNA Fragmentation by 16K hPRL in Vascular Endothelial Cells 
The level of DNA fragmentation associated with apoptosis was estimated by measuring the levels of cytosolic 
mono- and oligonucleosomes with an enzyme-linked immunosorbent assay (ELISA) (25). Experiments were 
performed in BBE cells deprived of serum [0.5% calf serum (CS)] for 2 days, a treatment that caused a 5-fold 
increase in nucleosome formation compared with cells cultured in 10% CS (Fig. 1A). Treatment with 2 or 10 nΜ 
16K hPRL for the second day of serum deprivation increased DNA fragmentation 2.3- and 4.4-fold compared 
with cells cultured in 0.5% CS, respectively. Interestingly, bFGF (0.5 nΜ) partially reversed the effect of 10 nΜ 
16K hPRL by 50%. To a lesser degree, treatment with VEGF also reduced the effect of 10 nΜ 16K hPRL by 
32%. 
The effect of 16K hPRL was similar in other bovine vascular endothelial cells including aortic endothelial 
(BAE) and the adrenal capillary endothelial (BAC) cells (Fig. 1B and data not shown). Serum deprivation of 
BAE cells increased DNA fragmentation 2-fold, while 2 nΜ 16K hPRL caused a further 5-fold increase. 
Treatment with 0.5 ∩Μ bFGF had no effect on the serum deprivation-induced effect; however, it reduced the 
increase by 16K hPRL by 25% (Fig. 1B). 
The action of 16K hPRL on DNA fragmentation was dose dependent. Increasing concentrations of 16K hPRL 
from 0.1 to 25 nΜ caused an exponential increase in DNA fragmentation in BBE cells (Fig. 1C). The highest 
concentration of 16K hPRL caused a 14-fold increase in DNA fragmentation as compared with 0.5% CS. The 
first significant increase in DNA fragmentation (2-fold) after treatment with 2 nΜ 16K hPRL was detectable at 1 
h in floating cells and at 2 h in attached cells (Fig. 1D). 16K hPRL-induced DNA fragmentation continued to 
increase for up to 24 h. The time course of the response in floating and attached cells was parallel for 8 h, but 
was then divergent, as it increased linearly in attached cells and plateaued in floating cells. 
To distinguish the effect of 16K hPRL on apoptosis from that of serum deprivation, we studied the effect of 16K 
hPRL on DNA fragmentation in different concentrations of serum in BBE cells. Increasing serum concentration 
decreased the amplitude of 16K hPRL-induced DNA fragmentation (Fig. 1E). As previously observed in BBE 
cells cultured in 0.5% CS, 2 and 10 nΜ 16K hPRL caused a 2- and 4-fold increase in DNA fragmentation, 
respectively. In 1% and 5% CS, treatment with 10 nΜ 16K hPRL induced a 4- and 10-fold increase in DNA 
fragmentation compared with the untreated control, respectively. Finally, in 10% CS, 2 and 10 nΜ 16K hPRL 
caused a 3- and 8-fold increase in DNA fragmentation, respectively (Fig. 1E). These results show that the 
stimulation of DNA fragmentation by 16K hPRL is not dependent on serum concentration. In human umbilical 
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vein endothelial (HUVE) cells, similar results were obtained. In 10% FCS, 1 and 10 nΜ 16K hPRL caused a 3.2- 
and 6.5-fold increase in DNA fragmentation, respectively (Fig. 1F). Interestingly, tumor necrosis factor-α 
(TNFα) (5 ng/ml) had no significant effect on nucleosome formation in 10% FCS, while it caused a 7.1-fold 
increase under serum-starved conditions. Finally, endotoxin standards-1 [E-Toxate kit, Sigma, St. Louis, MO; 10 
endotoxin units (EU)/ml] and -2 (Re 595, Sigma, 5 ng/ml) induced a 3.5 ± 0.2 and 4.4 ± 0.3 fold increase DNA 
fragmentation, respectively, which were significantly less than the 6.5 ± 0.3 fold increase due to 10 nΜ 16K 
hPRL (n = 5, P < 0.05). 
Specificity of 16K hPRL Preparation 
Since the 16K hPRL was produced in Escherichia coli it was important to demonstrate that the activity of the 
preparation used was not caused by a contaminant, e.g. endotoxin. A well defined property of endotoxin [or 
lipopolysaccharide (LPS)] in many cultured cells is the induction of programmed cell death (26, 27). In BBE 
cells, while 0.5 EU/ml endotoxin-1 had no effect (Fig. 1A), the first detectable increase in DNA fragmentation 
was observed at a concentration of 1 EU/ml of endotoxin-1, which caused a significant 2-fold increase vs. 0.5% 
CS control (P < 0.05) (data not shown). Treatment with 10 nΜ 16K hPRL increased DNA fragmentation 5.7-
fold, while treatment with 10 EU/ml endotoxin-1 caused a similar 6.1-fold increase compared with culture in 
0.5% CS (Fig. 2). This is 1300 times the amount of endotoxin present in 320 ng of 16K hPRL preparation used 
throughout the study (amount present in 2 ml of a 10 nΜ solution). 
Heat denaturation of 16K hPRL by boiling the sample for 2 min before adding it to the cells completely inhibited 
the 16K hPRL stimulation of DNA fragmentation. Similarly, the complete digestion of 16K hPRL by treatment 
with trypsin abolished its activity (Fig. 2). Neither treatment had any effect on the action of endotoxin-1. 
Furthermore, pretreatment with 10 µg/ml (final concentration) of the endotoxin blocker, poly-myxin-B, 
completely abolished the endotoxin effect, but had no effect on the action of 16K hPRL. 
To further dissociate the action of 16K hPRL from endotoxin, we showed that 16K hPRL caused a 4.8-fold 
increase in DNA fragmentation over serum deprivation in HUVE cells, a response similar to that seen in BBE 
cells. In comparison 5 ng/ml of TNFα caused a similar 4.8-fold increase in DNA fragmentation, while 10 EU/ml 
of endotoxin-1 caused a 3.2-fold increase. However, in primary endometrial stromal cells and in endometrial 
epithelial (Ishikawa) cells, while 10 nΜ 61K hPRL had no effect on DNA fragmentation, 5 ng/ml of TNFα and 
10 EU/ml of endotoxin-1 stimulated DNA fragmentation in both cell types (Fig. 3, B and C). 
Immunoneutralization of 16K hPRL was able to block its ability to induce DNA fragmentation in BBE cells 
(Fig. 4A). Both a 1:500 and 1:1000 dilution of monoclonal antibodies 4G7 (16K hPRL specific) or 6E4 
(recognizes both 16K hPRL and intact 23-kDa hPRL) inhibited 16K hPRL activity. However, preincubation of 
16K hPRL with a 1:500 dilution of an unrelated monoclonal antibody (Ctrl) had no effect on the stimulation of 
DNA fragmentation. Monoclonal antibodies 6E4 and 4G7 (1:500 dilution) also abolished 16K hPRL activity in 
HUVE cells, but had no effect on TNFα and endotoxin-2 activity (Fig. 4B). Finally, a neutralizing antibody 
against human TNFα was able to block the TNFα effect, but neither the 16K hPRL nor the endotoxin-2 effects. 
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Fig. 1. 16K hPRL Induces DNA Fragmentation in Bovine Endothelial Cells.  
A, BBE cells were cultured in 0.5% CS or 10% CS for 24h. For a second 24 h cells were cultured in 0.5% or 10% CS, or were treated with 
0.5 nM bFGF, 2 nM VEGF, 2 or 10 nM 16K hPRL, or 16K hPRL in combination with the mitogens in 0.5% CS. If not mentioned in the 
figure legend, this design was used throughout the studies. Endotoxin-1 (0.5 EU/ml) was added as a control for endotoxin contamination in 
the 16KhPRL preparation. DNA fragmentation was measured using an ELISA assay and is expressed as an enrichment factor (ratio of the 
absorbance of the sample to that measured for 10% CS). Each bar represents the mean ± SD, n = 6. B, Similar experiments were performed in 
bovine aortic endothelial (BAE) cells. The caspase inhibitor, z-VAD-fmk (20 µM), was added to determine whether the ability of 16K hPRL 
to stimulate DNA fragmentation in BAE cells depended on caspase activation. Each bar represents the mean ± SD, n = 4. C, Dose-dependent 
stimulation of DNA fragmentation by increasing concentrations of 16K hPRL in BBE cells. Each bar represents the mean ± SD, n = 3.             
The asterisk denotes a P value of < 0.05 vs. 0.5% CS control. D, Kinetics of 16K hPRL-induced BBE cell DNA fragmentation. Cells were 
cultured in 0.5% CS for 24 h and subsequently treated or not (open square and circle) with 2 nM 16K hPRL for the indicated time (filled 
square and circle). DNA fragmentation was measured in cells attached to the plastic dish (square) or in cells floating in the conditioned 
medium (circle). Each point represents the mean ± SD, n = 3. (E and F) To test whether the stimulation of DNA fragmentation by 16K hPRL 
was dependent on serum concentration, BBE cells were cultured in 0.5, 1, 5, or 10% CS for 48 h, while HUVE cells were cultured in 0% or 
10% serum. E, Cells were treated with nothing or 2, or 10 nM 16K hPRL for the last 24 h. F, Cells were treated with nothing, 1 or 10 nM 
16K hPRL, 5 ng/ml TNFα, 10 EU/ml endotoxin-1, or 5 ng/ml endotoxin-2. Each bar represents the mean ± SD, n = 5. The asterisk denotes a 
P value of < 0.05 vs. the nonstimulated control. 
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Fig. 2. Stimulation of DNA Fragmentation by 16K hPRL Is Not Dependent on Endotoxin Contamination. BBE 
cells were cultured in 0.5% or 10% CS and treated for 24 h with 10 nΜ 16K hPRL or 10 EU/ml endotoxin-1. 16K hPRL and endotoxin 
samples were also pretreated with Poly-myxin-B, boiling for 2 min, and trypsin digestion before being added to the cells. Each bar represents 




Fig. 3. 16K hPRL Induces DNA Fragmentation Specifically in Endothelial Cells. HUVE (A), human primary stromal 
endometrial (B), and human epithelial endometrial (C) cells were cultures in 10% serum or serum starved and treated for 24 h with either 10 
nM 16K hPRL, 5 ng/ml TNFα, or 10 EU/ml endotoxin-1. Each bar represents the mean ± SD, n = 4. The asterisk denotes a P value of < 0.05 
vs. the serum-starved control. 
 
 
These results demonstrate that the ability of the 16K hPRL preparations to stimulate DNA fragmentation was 
dependent on the activity of the peptide, and not on endotoxin or contaminating proteins in the preparation. The 
results also show that the action of 16K hPRL is specific for vascular endothelial cells. Furthermore, the 
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Fig. 4. Immunoneutralization of 16K hPRL Effect.  
ABBE cells were cultured in 0.5% or 10% CS and treated for 24 h. Samples containing 10 nM 16K hPRL were preincu-bated with either a 
monoclonal antibody that recognizes both native 23 kDa hPRL and 16K hPRL (6E4), a monoclonal antibody that is specific for 16K hPRL 
(4G7), or a control monoclonal antibody that is unrelated to 16K hPRL (Ctrl). B, HUVE cells were cultured in 10% serum or serum starved 
and treated for 24 h with 10 nM 16K hPRL, 5 ng/ml TNFα, or 5 ng/ml endotoxin-2. Indicated samples were preincubated with the 
monoclonal antibodies 6E4 or 4G7, or an immuno-neutralizing antibody specific for human TNFα, or the control monoclonal antibody 




Action of 16K hPRL Is Not Mediated via PRL or GH Receptors 
To demonstrate that 16K hPRL is not interacting with the GH or PRL receptor family to transduce its signal, we 
tested the effect of hGH and hPRL alone or in combination with 16K hPRL (Fig. 5). Addition of 10 and 50 nΜ of 
either recombinant hGH or hPRL alone after serum deprivation of BBE cells had no significant effects on DNA 
fragmentation. Once again these results argue against the possibility that the action of 16K hPRL is due to 
endotoxin contamination, since both recombinant hPRL and hGH had no effect on DNA fragmentation even 
though the concentration used had equivalent or higher endotoxin content than the 16K hPRL preparation. 
Furthermore, addition of 25 times more hGH or hPRL (50 n M) had no antagonistic effect on the ability of 2 nΜ 
16K hPRL to stimulate DNA fragmentation (Fig. 5). The results suggested that, as for inhibition of mitogen-
induced cell proliferation (11) or activation of PAI-1 expression (19), the 16K hPRL effects are not mediated by 
the PRL or GH receptors, but rather by a yet unknown type of receptor. 
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Effect of 16K hPRL on DNA Cell Content 
To directly investigate the effect of 16K hPRL on the number of cells entering programmed cell death, we 
analyzed the DNA content of 16K hPRL-treated BBE cells using flow cytometry of propidium iodide-stained 
cells. After 2 days of serum deprivation, BBE cells were relatively well synchronized in G0/G1 phase (Fig. 6A, 
top panel), with 17% of the cells having reduced DNA content (undergoing programmed cell death). After 24 h 
of 16K hPRL treatment (2 nΜ), more than 50% of the cells were undergoing apoptosis. Treatment with 16K 
hPRL drastically diminished the population of cells in G2/M phase, as well as the population of cells in G0/G1, 
phase (Fig. 6A, bottom panel). Kinetically, we observed the same pattern of changes in DNA content after 16K 
hPRL treatment as had been observed for DNA fragmentation (Fig. 6B). The dying cell population doubled after 
1 h of treatment and was still increasing at 24 h. These results indicate that 16K hPRL not only increased the 
DNA fragmentation in cells already undergoing apoptosis after serum deprivation, but also recruited new cells 
into this pathway. 
Similar effects on DNA content were observed when experiments were performed in 10% CS. Cells cultured in 
10% CS showed three distinct populations, 52% of the cell being in G0/G1, phase, 38% being in S or G2/M 
phases, and only 10% of the cells undergoing programmed cell death (Fig. 6C, top panel). After 24 h treatment 
with 2 nΜ 16K hPRL, the population of cells undergoing mitosis was dramatically diminished, to 7%, as was the 
population of cells in G0/G1 phase (24%). A similar percentage of cells (68%) were undergoing apoptosis in 10% 
CS as seen with 0.5% CS (50%) (Fig. 6C, bottom panel). Kinetically, we observed the same dynamics of the 
changes in DNA content after 16K hPRL treatment as seen for cells cultured in 0.5% CS. The apoptotic cell 
population doubled after 1 h and was still growing between 8 and 24 h (Fig. 6D). 
 
 
Fig. 5. Effect of 16K hPRL Is Not Mediated by the GH or PRL Receptors 
BBE cells were cultured in normal 10% CS conditions, and then serum deprived or not for 24 h, and finally 
treated for another 24 h with increasing concentrations of hGH or hPRL alone, with 2 nM 16K hPRL alone, or 
in combination with 50 nM hGH or hPRL to test the agonistic or antagonistic effects of 16K hPRL to hPRL and 
hGH. Each bar represents the mean ± SD, n = 3. The asterisk denotes a P value of < 0.05 vs. 0.5% CS control. 
 
 
16K hPRL Activates the Caspase Cascade 
We then asked whether the stimulation of apoptosis by 16 K hPRL was associated with activation of the caspase 
cascade. By Western blotting the 32-kDa proform of caspase 3 was expressed in BBE cells before and after 
serum deprivation (Fig. 7A). The 17-kDa active subunit of caspase 3 was not present in cells cultured in 10% 
CS, while after culture in 0.5% CS for 24 h a faint 17-kDa band corresponding to the active subunit of caspase 3 
began to appear. Treatment with 16K hPRL alone or in combination with bFGF induced a large increase in the 
Published in: Mol Endocrinol (2000), vol. 14, iss. 10, pp. 1536-1549 
Status: Postprint (Author’s version) 
 
formation of the active 17-kDa form, while the amount of the 32-kDa proform was decreased (treatment with 
16K hPRL in combination with bFGF) or unchanged (treatment with 16K hPRL alone). 
To confirm that the increase in the 17-kDa band was associated with an increase in caspase 3 activity, we 
analyzed one of the known substrates of caspase 3, the poly(ADP-ribose) polymerase (PARP). This 116-kDa 
DNA repair enzyme is cleaved to an inactive 85-kDa fragment by caspase 3 (Fig. 7B, upper panel).                       
By densitometric analysis, treatment with 16K hPRL resulted in the conversion of 65% of PARP into the 
inactive 85-kDa fragment (Fig. 7B, lower panel). Serum deprivation only resulted in the conversion of 15% of 
the PARP, while at the basal level, in 10% CS, the conversion level was 5%. Treatment with bFGF was not able 
to significantly reverse the effect of 16K hPRL. We then asked whether treatment with 16K hPRL activated 
caspase 1, a potential upstream step in the caspase cascade. Caspase 1 has been shown to activate caspase 3 in 
response to TNFα (28), as well as during photooxidative stress (29). By Western blotting, caspase 1 was present 
in BBE cells as the inactive 45-kDa proenzyme (Fig. 7C). Treatment with 16K hPRL, at two different doses        
(2 and 10 nΜ), or in combination with bFGF, stimulated the formation of the 20-kDa fragment of caspase 1, 
known to be part of the active protease complex. This band was absent before serum deprivation and in most of 
the experiments after serum deprivation, or after treatment with bFGF or native hPRL. The effect of 10 nΜ 16K 
hPRL on caspase 1activation was independent of serum concentration, since it was observed in 1, 5, and 10% CS 
(Fig. 7D). Treatment with 1 nΜ 16K hPRL was capable of inducing the formation of the 20-kDa fragment in 
10% CS, while serum deprivation resulted in the appearance of only a faint band (Fig. 7D). Endotoxin-1                  
(1 EU/ml) was not able to induce the processing of caspase 1 to its active form (Fig. 7C). The effect of 16K 
hPRL was inhibited by treatment with the general caspase inhibitor, z-VAD (30). A similar effect of z-VAD 
treatment was observed in BAE cells. The increase in DNA fragmentation induced by 2 nΜ 16K hPRL in 0.5% 
CS was abolished by pretreatment of the cells with 20 µM z-VAD (Fig. 1B). These results were consistent with 
the idea that 16K hPRL specifically activated an apo-ptotic cascade involving the activation of caspase 1. 
The kinetics of caspases 1 and 3 processing were similar under 0.5 and 10% CS culture conditions (Fig. 7E, 
0.5% CS and 10% CS). The active forms of the proteases were observed as early as 15 min after treatment with 2 
nΜ 16K hPRL. By 30 min, activation of caspase 3 resulted in the cleavage of PARP (116 kDa), resulting in the 
appearance of the inactive 85-kDa form. The 85-kDa cleaved form was observed throughout the 24-h treatment, 
while the intact PARP could no longer be observed after 3 h in 10% CS and was almost undetectable in 0.5% 
CS. The inhibitor of the caspase-activated DNase (ICAD) (31, 32), another potential substrate of caspase 3, was 
cleaved to its inactive 34-kDa form in a similar pattern by treatment with 16K hPRL. This suggests that 16K 
hPRL specifically activated an apoptotic cascade involving the activation of caspases, like caspase 1 or 3, and 
subsequently the inactivation of downstream substrates like PARP or ICAD. 
Effects of 16K hPRL on Expression of the Bcl-2 Family 
Among the large Bcl-2 protein family, we analyzed the expression of one antiapoptotic protein, Bcl-2, and two 
proapoptotic proteins, Bax and Bak, by Western blotting (33). After serum deprivation, the amount of Bcl-2 was 
markedly increased (Fig. 8A). Treatment of the BBE cells with 2 or 10 nΜ 16K hPRL did not significantly 
modify this increased expression. The levels of Bax and Bak were unchanged after culture in 0.5% CS or 
treatment with 2 or 10 nΜ 16K hPRL. Densitometric analysis and expression of the results as the Bcl-2/Bax ratio 
also showed no changes (Fig. 8B). 
Similarly, in kinetic studies, treatment with 2 nM 16K hPRL had little effect on the level of Bcl-2, Bax, or Bak 
over a 24-h period (Fig. 8C, 0.5% CS and 10% CS). However, treatment with 16K hPRL stimulated the 
conversion of Bcl-X from its antiapoptotic 29-kDa form (Bcl-XL) to its proapoptotic 21-kDa form (Bcl-Xs) (34). 
Clear increases in Bcl-Xs were observed 1 h after treatment with 16K hPRL, and at 3 h, 50 and 20% of Bcl-XL 
was converted to Bcl-Xs in 0.5% CS and 10% CS, respectively. These results suggest that 16K hPRL had no 
major effect on Bcl-2, Bax, and Bak levels. However, stimulation of the conversion of Bcl-XL to inactive Bcl-Xs 
by 16K hPRL is consistent with the activation of apoptosis. This observation may help to explain why the 
increase in Bcl-2 expression observed after culture in 0.5% CS was not sufficient to prevent the apoptotic effect 
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Fig. 6. Stimulation of Apoptosis by 16K hPRL as Determined by DNA Content Analysis by Flow Cytometry.  
BBE cells were cultured in 0.5% CS (A) or 10% CS (C) for 24 h and then treated with nothing (Control) or 2 nM 16K hPRLfor 24 h. Events 
falling under the 100 (0 to 100) FL2 channel scale are considered as apoptotic events resulting from DNA fragmentation. Percents represent 
the proportion of gated cells undergoing apoptosis. Position of the G0/G1, S, G2/M, and apoptosis phase is indicated on top of the right panel 
(A). B and D, Percentage of cells undergoing apoptosis after treatment with 2 nM 16K hPRL with time. Each point represents the mean value 
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Fig. 7. Activation of Caspases 1 and 3 by 16K hPRL 
A, Western blot analysis of caspase 3 in lysates of BBE cells treated for 24 h with 0.5 nM bFGF, 2 nM 16K hPRL, or both in 0.5% CS. The 
molecular masses of the inactive proform (32 kDa), partially processed inactive form (28 kDa), and active subunit (17 kDa) of caspase 3 are 
indicated on the left side. B, upper panel: Western blot analysis using an anti-PARP antibody (PARP). The active 116 kDa form of PARP 
was converted to the inactive 85 kDa form after activation of caspase 3. B, bottom panel: The mean ± SD (n = 4) relative intensity of the 116 
and 85 kDa bands determined by ImageQuant Software (Molecular Dynamics, Inc.). The asterisk denotes a P value of < 0.05 vs. 0.5% CS 
control. C, Western blot analysis of the inactive 45 kDa proform, partially processed inactive 30 kDa form, and 20 kDa active form of 
caspase 1, after treatment with 2 or 10 nM 16K hPRL, 0.5 nM bFGF, and zVAD, alone or in combination. The effects of treatment with 23K 
hPRL or endotoxin-1 were also tested. D, Effect of CS concentration (1%, 5%, 10%, or 0.5%) on the activation of caspase 1 by 16K hPRL. 
E, Time course of the activation of caspases 1 and 3 and inactivation of caspase 3 substrates, PARP and ICAD, after treatment with 2 nΜ 16K 
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Fig. 8. Effect of Treatment with 16K hPRL on Levels of Bcl-2, Bax, Bak, and Bcl-X 
A, Western blot analysis of Bcl-2, Bax, and Bak after treatment with 2 or 10 nM 16K hPRL in 0.5% CS as compared with culture in 0.5 or 
10% CS. Size of the corresponding proteins was indicated on the right side. B, The relative intensity of 26 and 23 kDa bands, corresponding 
to Bcl-2 and Bax, respectively, and the mean (n = 2) Bcl-2/Bax ratio calculated from the intensity of the bands determined by the 
ImageQuant Software (Molecular Dynamics, Inc.). C, Time course of the effect of treatment with 2 nΜ 16K hPRL on the level of Bcl-2, Bcl-
X, Bax, and Bak as analyzed by Western blot in 0.5 and 10% CS. The 29 kDa antiapoptotic form of Bcl-X (Bcl-XL) was converted to the 21 




These findings demonstrate that 16K hPRL specifically stimulates programmed cell death of vascular endothelial 
cells by multiple criteria: DNA fragmentation; fluorescence-activated cell sorting (FACS) analysis of BBE cell 
DNA content; activation of the caspase cascade; and regulation of the Bcl-2 family members. In addition, 
treatment with 16K hPRL inhibited entry of BBE cells into the cell cycle at the G0/G1, transition. After 24 h of 
16K hPRL treatment, more than 50% of the cells were undergoing apoptosis, while the reminder of cells were 
mainly in the G0/G1 state. These data support the earlier observations that 16K hPRL inhibits FGF-induced BBE 
cell proliferation, which was followed by rounding up of the cells (11); they show in addition that 16K hPRL 
stimulates apoptosis. This induction of programmed cell death was dependent on the caspase cascade activation, 
as well as the inacti-vation of Bcl-X. 
Bacterial endotoxin (LPS) has been shown to increase PAI-1 expression, stimulate apoptosis, and inhibit cell 
proliferation of endothelial cells (35, 36). The observation regarding the similarity of the signaling pathways 
activated by LPS and 16K hPRL made it imperative to demonstrate that the antiangiogenic actions of the 
recombinant 16K hPRL preparations was not due to contamination with endotoxin. First the endotoxin level of 
the 16K hPRL preparation used in this study was more than a 1,000-fold less than necessary to observe any 
biological effect. The ability of the 16K hPRL preparations to stimulate DNA fragmentation could be completely 
blocked by digestion of the protein with trypsin, or denaturation of the protein by boiling. The action of LPS was 
unaffected by boiling but was blocked by the addition of polymyxin-B. However, polymyxin-B treatment had no 
effect on the action of 16K hPRL. That the activity of the 16K hPRL could depend on complexing with LPS in 
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the preparations appears unlikely, since for every 3,000 16K hPRL molecules, there is approximately 1 LPS 
molecule. Human endothelial cells, especially HUVE cells, have been described as 1,000 times less sensitive to 
endotoxin than bovine endothelial cells (37). However, we found that HUVE cells responded to 16K PRL (10 
nΜ) and TNFα (5 ng/ml) in a similar manner, and to a lesser degree to endotoxin-1 (10 EU/ml). We also 
demonstrated that the response to 16K hPRL was specific for endothelial cells, while endotoxin and TNFα 
activated DNA fragmentation in endothelial cells as well as stromal and epithelial cells. Most importantly, the 
ability of 16K hPRL to activate DNA fragmentation in both bovine and human endothelial cells was abolished 
by immunoneutralization using specific monoclonal antibodies. The unlikely possibility that the activity of the 
recombinant preparations is due to some unknown heat-sensitive contaminant that co-precipitates with 16K 
hPRL cannot be ruled out. 
Within 15 min 16K hPRL treatment resulted in conversion of the inactive proforms of caspase 1 and 3 to their 
active fragments. Activation of caspase 3 was directly confirmed by the cleavage and inactivation of the 
substrates, PARP and ICAD. Cleavage of both PARP (38) and ICAD (31, 39) by caspase 3 have been shown to 
be important steps in the apoptotic pathway. Inactivation of ICAD allows caspase-activated DNase (CAD) to 
enter the nucleus and degrade genomic DNA, while inactivation of PARP inhibits its DNA repair activity. The 
combination of these two events facilitates cellular disassembly and ensures the completion and commitment of 
the cell to the apoptotic pathway. Activation of the caspase cascade was essential for the apoptotic action of 16K 
hPRL. The processing of caspase 1 and the stimulation of DNA fragmentation by 16K hPRL were totally 
blocked by treatment with the caspase inhibitor, z-VAD. 
Although the levels of Bcl-2, Bax, and Bak were unaffected by treatment with 16K hPRL, the conversion of Bcl-
X was stimulated from its antiapoptotic form, Bcl-XL, to its proapoptotic form, Bcl-Xs. Increased expression of 
Bcl-XL appears to play an important role in the ability of nuclear factor (NF)-κB to inhibit apoptosis (40). The 
inhibition of the antiapoptotic action of Bcl-XL by 16K hPRL treatment is consistent with its stimulation of 
apoptosis. 
The signaling mechanisms mediating the multiple antiangiogenic actions of 16K hPRL on vascular endothelial 
cells are still poorly understood. Although a specific, high-affinity, saturable binding site for 16K hPRL has been 
described on capillary endothelial cells (15), the identity of the receptor molecule is unknown. The effects of 
16K hPRL are not mediated via an action on the PRL receptor as an agonist or antagonist. As with the effects of 
16K hPRL on cell proliferation (11) and stimulation of PAI-1 expression (19), intact 23-kDa hPRL has no effect 
on stimulating apoptosis or inhibiting the ability of 16K hPRL to stimulate apoptosis. The question of how 
binding of 16K hPRL to its receptor activates the caspase cascade and apoptosis, inhibits activation of Ras and 
presumably cell proliferation, and increases the expression of PAI-1 remains unclear. However, activation of 
multiple signaling pathways appears to be the rule rather than the exception with ligands acting on endothelial 
cells. For example, another antiangiogenic factor throm-bospondin inhibits endothelial cell proliferation and 
stimulates apoptosis  (21, 41, 42). Several other cytokines have also been shown to affect multiple signaling 
pathways in endothelial cells, e.g. TNFα and transforming growth factor-β (TGFβ) (43-45). 
Tumor growth and progression have been shown to be dependent on development of a new microvascu-lature 
(2). Inhibition of the action of the angiogenic factor VEGF has been shown to result in tumor endothelial cell 
apoptosis and tumor necrosis (46). As previously seen, withdrawal of bFGF and/or serum induces endothelial 
cell apoptosis in vitro (47). These observations support the importance of the regulation of apoptosis as a control 
mechanism for tumor angio-genesis. The ability of 16K hPRL to inhibit the stimulation of endothelial cell 
proliferation by the angiogenic factors VEGF and bFGF and to directly stimulate apoptosis strongly supports the 
potential of 16K hPRL as an antitumor drug. 
In conclusion, we have clearly demonstrated that 16K hPRL protein in our recombinant preparation is 
responsible for promoting programmed cell death of cultured endothelial cells. Furthermore, we have presented 
detailed functional evidence that the caspase cascade is fundamental for 16K hPRL-induced apoptosis in a dose- 
and time-dependent manner. These findings reveal a novel and important mechanism for 16K hPRL to regulate 
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MATERIALS AND METHODS 
Production of Recombinant Proteins 
For the production of recombinant 16K hPRL the cDNA encoding hPRL minus the corresponding signal peptide 
was inserted into the pT7L expression vector (48). An ATG was genetically engineered 5' to the first codon of 
the cDNA. The codon for Cys 58 (TGC) was mutated to a Ser codon (TCC) to prevent the formation of incorrect 
disulfide bounds during refolding of the 16K hPRL (11). To get high levels of expression of the recombinant 
protein in E. coli the full-length hPRL molecule was expressed, purified, and then cleaved (14). To accomplish 
this the nucleotide sequence coding for amino acids 139-144 (Pro-Glu-Thr-Lys-Glu-Asn: CCT-GAA-ACC-
AAA-GAA-AAT) in hPRL was replaced with the nucleotide sequence coding for the cleavage site of IgA 
protease (Pro-Arg-Pro-Pro-Thr-Pro: CCT-AGA-CCC-CCA-ACA-CCT). Cleavage occurred between Pro 142 
and Thr 143. 
In brief, intact protein expression was induced in E. coli BL21 DE3 with isopropyl β-D-thiogalactopyranoside 
and the inclusion bodies were isolated. After washing, the inclusion bodies were solubilized in denaturation 
buffer (8 M urea, 20 mM ethanolamine-HCI, pH 10, 1% 2-mercaptoethanol, 0.5 mM PMSF) for 10 min at 55 C 
and overnight at room temperature. After renaturation by dialysis against 20 mM ethanolamine-HCI, pH 9, the 
proteins were purified as previously described (48). The mutated hPRL was enzymatically cleaved with IgA 
protease (0.05%, 25 C, overnight; Roche Molecular Chemicals, Indianapolis, IN). The 16K hPRL was purified 
by ion-exchange chromatography (HiTrap Q, Pharmacia Biotech, Piscataway, NJ). 
The purity of each recombinant protein exceeded 95% as estimated by silver staining. The Limulus amoebocyte 
lysate assay (E-Toxate kit, Sigma) was used to detect and quantify endotoxin levels. The endotoxin level of the 
16K hPRL preparation used in the studies was 47 × 10-6 EU/ng protein. 
Cell Culture 
BBE and BAE cells were isolated as previously described (Refs. 49 and 50), respectively. The cells were grown 
and serially passaged in low glucose DMEM supplemented with 10% calf serum (CS), 2 ITIM L-glutamine, and 
antibiotics (100 U of penicillin/streptomycin per ml and 2.5 mg of fungizone per ml). Recombinant human basic 
FGF (bFGF, Promega Corp., Madison, Wl) was added (1 ng/ml) to the cultures every other day. Experiments 
were initiated with confluent cells between passages 6-12. Primary human umbilical vein endothelial (HUVE) 
cells were obtained from Clonetics Corp. (San Diego, CA), grown according to specification, and retained for up 
to six passages. Primary human endometrial stromal cells and human endometrial epithelial cell line (Ish-ikawa) 
were kindly provided by Drs. R. N. Taylor and D. Lebovic (University of California, San Francisco). Primary 
stromal cells were prepared and cultured from endometrial biopsies as described (51). Ishikawa cells were 
routinely grown in DMEM/F-12 (1:1) supplemented with 10% FBS, penicillin-streptomycin, and sodium 
pyruvate. 
Cell Stimulation and Preparation of Cell Extracts 
Confluent cell cultures were dispersed and plated at the density of 15-20 × 103 cells/cm2 culture plate (one plate 
per condition) in appropriate media. Thirty six hours after plating, cells were either serum starved or left in 
medium containing 10% serum for another 24 h. Cells were left untreated or treated with 2 nM recombinant 
human VEGF165 (VEGF, Genentech, Inc., South San Francisco, CA), 2 nM VEGF plus 2 nΜ 16K hPRL, 0.5 nΜ 
bFGF (Promega Corp.), 0.5 nΜ bFGF plus 2 nM 16K hPRL, various concentrations of 16K hPRL, recombinant 
human TNFα (Pepro Tech, Rocky Hill, NJ), en-dotoxin-1 (Limulus amoebocyte lysate, E-Toxate kit, Sigma) or 
endotoxin-2 (Salmonella minnesota Re 595, a minimal naturally occurring endotoxic structure of LPS, Sigma) 
for 24 h. 
Incubations were terminated by aspiration of the medium, two washes with ice-cold PBS, and addition of 200 µl 
of lysis buffer (1% Triton X-100 lysis buffer containing 20 ITIM Tris-HCI, pH 8.0, 137 ITIM NaCl, 10% (vol/vol) 
glycerol, 2 mM EDTA, with (for detection of nuclear proteins) or without 3 M urea, 1 mM pefabloc, 0.14 U 
aprotinin, 20 µM leupeptin, and 1 mM sodium orthovanadate) at 4 C as previously described (16). 
The peptidyl fluoromethyl ketone (fmk) caspase inhibitor z-VAD-fmk (20 µM, Enzyme Systems Products, 
Livermore, CA) was added at the time cells were serum deprived and/or treatment added. 
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Endotoxin Controls 
To study the effect of the addition of endotoxin (LPS), several approaches were used to demonstrate that the 
apoptotic activity of 16K hPRL preparations was not due to endotoxin contamination. Polymyxin-B (Sigma), an 
antibiotic that binds and inactivates LPS, was preincubated with samples for 10 min at 37 C in a final 
concentration of 10 µg/ml. Alternatively, 16K hPRL activity was destroyed in the sample to be added to the 
culture cells by boiling for 2 min, or proteolytic digestion with trypsin (Sigma) for 16 h at 37 C according to the 
manufacturer's protocol. Efficiency of the digestion was tested by Coomassie blue staining (Bio-Rad 
Laboratories, Inc.) of SDS-PAGE gels (16% acrylamide). Finally 16K hPRL activity was immunoneutralized by 
preincubation for 45 min at 4 C in serum free medium containing either a specific monoclonal antibody for 16K 
hPRL (4G7, Dr. Martial), a monoclonal antibody that recognizes both the 23 kDa native hPRL and 16K hPRL 
with equal potency (6E4, Dr. Martial) and, as controls, an unrelated monoclonal antibody (pp54) or a 
neutralizing monoclonal antibody antihuman TNFα (Upstate Biotechnology, Inc., Lake Placid, NY; 1:750 
dilution). 
DNA Fragmentation ELISA Assay 
A hallmark of programmed cell death by apoptosis is the formation of multinucleosomal sized genomic DNA 
fragments. DNA fragments are multiples of 180 bp subunits associated with core histones. Accumulation of 
mono- and oligonucleosomes into the cytoplasm of apoptotic cells is due to the fact that DNA fragmentation 
occurs before the breakdown of the plasma membrane, which is not the case with cell death by necrosis. The 
levels of mono- and oligo-nucleosomal DNA released in the cytosol of apoptotic cells were measured using the 
Cell Death Detection ELISA kit (Roche Molecular Biochemicals, Indianapolis, IN). This is a quantitative 
sandwich-enzyme-immunoassay using antibodies against DNA and histones. Levels of DNA fragmentation were 
expressed as an enrichment factor, calculated by dividing the absorbance of a given sample by the absorbance of 
the corresponding 10% CS control. 
DNA Content Analysis 
BBE cells were cultured and treated as described above. The cells were harvested by trypsinization, washed in 
cold PBS, and fixed in 80% ethanol in PBS at 4 C for 30 min. After centrifugation, the cell pellets were 
suspended into PBS and passed through a 70 µm nylon cell strainer (Falcon). The cells were stained with 10 
µg/ml propidium iodide and treated with 200 µg/ml RNase A at 37 C for 30 min. The fluorescence of individual 
cells was measured with a FACScalibur cytoflu-orometer equipped with the CellQuest software (Becton 
Dickinson and Co., Franklin Lakes, NJ). 
Western Blotting 
To detect processing of apoptotic proteases (caspases 1 and 3), the cleavage of poly(ADP-ribose) polymerase 
(PARP), and to survey the protein expression of ICAD, Bax, Bak, Bcl2, Bcl-X, equal quantities of lysates from 
BBE cells were resolved by SDS/PAGE (8%, 12%, or 15%) and transferred to polyvinylidene fluoride 
membranes (Millipore Corp., Bedford, MA). Separate Western blots were performed using a variety of 
antibodies including an antihuman caspase 1 (ICE) rabbit polyclonal antibody (Upstate Biotechnology, Inc. 
1:1000 dilution) that recognizes the proenzyme of 45 kDa, the partially cleaved inactive form of 30 kDa, and the 
p20 subunit of active caspase 1 ; an antihuman caspase 3 (YAMA/Apopain/CPP32) rabbit polyclonal antibody 
(Upstate Biotechnology, Inc. 1:1000 dilution; Santa Cruz Biotechnology, Inc., 1:500 dilution) that recognizes the 
caspase 3 precursor (32 kDa), the partially processed inactive form of 28 kDa, and the p17 subunit of the active 
caspase 3; an antihuman PARP rabbit polyclonal antibody (Upstate Biotechnology, Inc. 1:750 dilution) that 
recognizes both the 116 kDa form of active PARP and its 85 kDa proteolytic fragment; an antihuman DFF-45/ 
ICAD rabbit polyclonal antibody (Upstate Biotechnology, Inc. 1:1000 dilution) that recognizes the N-terminal 
part of both the full-length molecule (45 kDa) and the caspase 3 generated form of approximately 34 kDa; an 
antihuman Bcl-2 oncoprotein mouse monoclonal antibody (Upstate Biotechnology, Inc. 1:500; Santa Cruz 
Biotechnology, Inc., 1:500 dilution) that recognizes a protein of 26 kDa; an antihuman Bak rabbit polyclonal 
antibody (Upstate Biotechnology, Inc. 1:1000 dilution) that recognizes a protein of 29 kDa; an antihuman Bax 
rabbit polyclonal antibody (Upstate Biotechnology, Inc. 1:500 dilution) that recognizes a protein of 23 kDa; and 
an antichicken Bcl-XL/Xs rabbit polyclonal antibody (Upstate Biotechnology, Inc. 1:1000 dilution) that 
recognizes both proteins of 21 (Bcl-Xs) and 29 kDa (Bcl-XL). Nuclear extract of human Hela, human A431 cells 
stimulated with or without EGF, and mouse 3T3 cell lysates were used appropriately as positive controls for all 
antibodies. Western blots were incubated with the appropriate antibody and then washed in Tris-buffered saline 
containing 0.1% Tween 20. Antigen-antibody complexes were detected with horseradish peroxidase-coupled 
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secondary antibodies and the enhanced chemiluminescence system (Renaissance, NEN Life Science Products, 
Boston, MA). Finally, the blots were developed on reflection NEF film (NEN Life Science Products). 
Statistical Analysis 
All values are expressed as mean ± SD. Comparisons between treatment conditions were assessed by one-way 
ANOVA with the post hoc analysis with the Student-Newman-Keuls test. Statistical significance was defined as 
a value of P < 0.05. 
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